-
TB-2-081
- names:
3-O-Formyl-20R,21-epoxyresibufogenin
- CAS号:
451470-55-6
MDL Number: - MF(分子式): C25H32O6 MW(分子量): 428.53
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | 3-O-Formyl-20R,21-epoxyresibufogenin |
| 英文别名 | TB-2-081; TB2081; TB 2 081; TB-2081; TB2-081; TB 2-081; TB-2 081 |
| CAS号 | 451470-55-6 |
| Inchi | InChI=1S/C25H32O6/c1-22-8-5-15(28-13-26)11-14(22)3-4-17-16(22)6-9-23(2)18(12-19-25(17,23)30-19)24-10-7-20(27)29-21(24)31-24/h7,10,13-19,21H,3-6,8-9,11-12H2,1-2H3/t14-,15+,16+,17-,18-,19-,21+,22+,23-,24-,25-/m1/s1 |
| InchiKey | CMYYMVGNLZUIOQ-AYFUEPLASA-N |
| 分子式 Formula | C25H32O6 |
| 分子量 Molecular Weight | 428.53 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | TB-2-081(CAS:451470-55-6):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | TB-2-081 is a antagonist of IL-6 signaling. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Remeniuk B, King T, Sukhtankar D, Nippert A, Li N, Li F, Cheng K, Rice KC, Porreca F. Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain. Pain. 2018 Apr;159(4):684-698. doi: 10.1097/j.pain.0000000000001139. PubMed PMID: 29300279; PubMed Central PMCID: PMC5911943. |
| [2]Boos TL, Cheng K, Greiner E, Deschamps JR, Jacobson AE, Rice KC. Configurational reassignment and improved preparation of the competitive IL-6 receptor antagonist 20R,21R-epoxyresibufogenin-3-formate. J Nat Prod. 2012 Apr 27;75(4):661-8. doi: 10.1021/np2008957. Epub 2012 Feb 23. PubMed PMID: 22360661; PubMed Central PMCID: PMC3351795. |
| [3] Vardanyan M, Melemedjian OK, Price TJ, Ossipov MH, Lai J, Roberts E, Boos TL, Deschamps JR, Jacobson AE, Rice KC, Porreca F. Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist. Pain. 2010 Nov;151(2):257-65. doi: 10.1016/j.pain.2010.05.022. Epub 2010 Jul 4. PubMed PMID: 20599324; PubMed Central PMCID: PMC3313485. |
| [4] Kino T, Boos TL, Sulima A, Siegel EM, Gold PW, Rice KC, Chrousos GP. 3-O-Formyl-20R,21-epoxyresibufogenin suppresses IL-6-type cytokine actions by targeting the glycoprotein 130 subunit: potential clinical implications. J Allergy Clin Immunol. 2007 Aug;120(2):437-44. Epub 2007 Apr 23. PubMed PMID: 17451794. |
| [5] Hayashi M, Rho MC, Fukami A, Enomoto A, Nonaka S, Sekiguchi Y, Yanagisawa T, Yamashita A, Nogawa T, Kamano Y, Komiyama K. Biological activity of a novel nonpeptide antagonist to the interleukin-6 receptor 20S,21-epoxy-resibufogenin-3-formate. J Pharmacol Exp Ther. 2002 Oct;303(1):104-9. PubMed PMID: 12235239. |
6: Li W, Shi X, Wang L, Guo T, Wei T, Cheng K, Rice KC, Kingery WS, Clark JD. Epidermal adrenergic signaling contributes to inflammation and pain sensitization in a rat model of complex regional pain syndrome. Pain. 2013 Aug;154(8):1224-36. doi: 10.1016/j.pain.2013.03.033. Epub 2013 Apr 12. PubMed PMID: 23718987; PubMed Central PMCID: PMC3713848.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


